Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Taro Yoneda
Long-Lasting Responses After Discontinuation of Nivolumab Treatment for Reasons Other Than Tumor Progression in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
Cancer Communications
Cancer Research
Oncology
The Measurement of Cough Response to Bronchoconstriction Induced by Methacholine Inhalation in Healthy Subjects: An Examination Using the Astograph Method
Experimental Lung Research
Respiratory Medicine
Pulmonary
Clinical Biochemistry
Molecular Biology
Related publications
P1.04-29 Second or Third Line Nivolumab Versus First Line Nivolumab in Patients With Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
179P: Nivolumab Monotherapy in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice in a Spanish Center
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Predictive Role of Plasmatic Biomarkers in Advanced Non-Small Cell Lung Cancer Treated by Nivolumab
OncoImmunology
Oncology
Allergy
Immunology
Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Cancer Research and Treatment
Cancer Research
Oncology
Treatment Results Including More Than Third-Line Chemotherapy for Patients With Advanced Non-Small Cell Lung Cancer
Oncology Letters
Cancer Research
Oncology
MA10.06 Impact of Immune-Related Adverse Events on Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Clinical Factors Associated With Early Progression and Grade 3–4 Toxicity in Patients With Advanced Non-Small-Cell Lung Cancers Treated With Nivolumab
PLoS ONE
Multidisciplinary
Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non‐Small Cell Lung Cancer Patients
Oncologist
Cancer Research
Medicine
Oncology
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
JAMA Oncology
Cancer Research
Oncology